For: | Rucci N, Sanità P, Monache SD, Alesse E, Angelucci A. Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets. World J Clin Oncol 2014; 5(3): 335-347 [PMID: PMC4127605 DOI: 10.5306/wjco.v5.i3.335] |
---|---|
URL: | https://www.wjgnet.com/2218-4333/full/v5/i3/335.htm |
Number | Citing Articles |
1 |
Qi Xiong, Lihai Zhang, Lingli Xin, Yanpan Gao, Ye Peng, Peifu Tang, Wei Ge. Proteomic study of different culture medium serum volume fractions on RANKL-dependent RAW264.7 cells differentiating into osteoclasts. Proteome Science 2015; 13(1) doi: 10.1186/s12953-015-0073-6
|
2 |
Liang Wang, Xiangyun Guo, Jinran Qin, Zikai Jin, Qingqing Liu, Chuanrui Sun, Kai Sun, Linghui Li, Xu Wei, Yili Zhang. Assessing the causal relationship between plasma proteins and osteoporosis: novel insights into pathological mechanisms and therapeutic implications. Osteoporosis International 2024; 35(11): 1973 doi: 10.1007/s00198-024-07225-y
|
3 |
Cintia Kazuko Tokuhara, Mariana Rodrigues Santesso, Gabriela Silva Neubern de Oliveira, Talita Mendes da Silva Ventura, Julio Toshimi Doyama, Willian Fernando Zambuzzi, Rodrigo Cardoso de Oliveira. Updating the role of matrix metalloproteinases in mineralized tissue and related diseases. Journal of Applied Oral Science 2019; 27 doi: 10.1590/1678-7757-2018-0596
|
4 |
Tayyeb Bahrami, Sharareh Mokmeli, Hossien Hossieni, Reza Pourpaknia, Zahra Makani, Arash Salmaninejad, Mehrdad A. Estiar, Ali Hossieni, Alieh Farshbaf. The molecular signature of breast cancer metastasis to bone. Anti-Cancer Drugs 2016; 27(9): 824 doi: 10.1097/CAD.0000000000000401
|
5 |
Samantha S. Dykes, Veronica S. Hughes, Jennifer M. Wiggins, Henrietta O. Fasanya, Mai Tanaka, Dietmar Siemann. Stromal cells in breast cancer as a potential therapeutic target. Oncotarget 2018; 9(34): 23761 doi: 10.18632/oncotarget.25245
|
6 |
Piotr Rhone, Kornel Bielawski, Katarzyna Ziołkowska, Danuta Rość, Barbara Ruszkowska-Ciastek. Low Pre-Treatment Count of Circulating Endothelial Progenitors as a Prognostic Biomarker of the High Risk of Breast Cancer Recurrence. Journal of Clinical Medicine 2019; 8(11): 1984 doi: 10.3390/jcm8111984
|
7 |
Chao Li, Yu Chen, Yong Gao, Xin Wang, Jiaqiang Wang, Peng Zhang, Xiaobo Hu, Lei Li, Weijun Tong, Zhigang Ren, Weitao Yao. A nanomedicine based on stoichiometric coordination of camptothecin and organoplatinum (II) for synergistic antitumor therapy. Acta Biomaterialia 2023; 164: 553 doi: 10.1016/j.actbio.2023.04.010
|
8 |
Marion Bertho, Julien Fraisse, Anne Patsouris, Paul Cottu, Monica Arnedos, David Pérol, Anne Jaffré, Anthony Goncalves, Marie-Paule Lebitasy, Véronique D’Hondt, Florence Dalenc, Jean-Marc Ferrero, Christelle Levy, Sandrine Dabakuyo, Roman Rouzier, Frédérique Penault-Llorca, Lionel Uwer, Jean-Christophe Eymard, Mathias Breton, Michaël Chevrot, Sébastien Thureau, Thierry Petit, Gaëtane Simon, Jean-Sébastien Frénel. Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. Therapeutic Advances in Medical Oncology 2021; 13 doi: 10.1177/1758835920987657
|
9 |
Gang Li, Jing Hu, Guohong Hu. Translational Research in Breast Cancer. Advances in Experimental Medicine and Biology 2017; 1026: 27 doi: 10.1007/978-981-10-6020-5_2
|
10 |
Paola Maroni, Paola Bendinelli, Daniele Morelli, Lorenzo Drago, Alessandro Luzzati, Giuseppe Perrucchini, Chiara Bonini, Emanuela Matteucci, Maria Desiderio. High SPARC Expression Starting from Dysplasia, Associated with Breast Carcinoma, Is Predictive for Bone Metastasis without Enhancement of Plasma Levels. International Journal of Molecular Sciences 2015; 16(12): 28108 doi: 10.3390/ijms161225997
|
11 |
Kerui Wu, Jiamei Feng, Feng Lyu, Fei Xing, Sambad Sharma, Yin Liu, Shih-Ying Wu, Dan Zhao, Abhishek Tyagi, Ravindra Pramod Deshpande, Xinhong Pei, Marco Gabril Ruiz, Hiroyuki Takahashi, Shunsuke Tsuzuki, Takahiro Kimura, Yin-yuan Mo, Yusuke Shiozawa, Ravi Singh, Kounosuke Watabe. Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer. Nature Communications 2021; 12(1) doi: 10.1038/s41467-021-25473-y
|
12 |
Soichiro Sasaki, Tomohisa Baba, Tatsunori Nishimura, Yoshihiro Hayakawa, Shin-ichi Hashimoto, Noriko Gotoh, Naofumi Mukaida. Essential roles of the interaction between cancer cell-derived chemokine, CCL4, and intra-bone CCR5-expressing fibroblasts in breast cancer bone metastasis. Cancer Letters 2016; 378(1): 23 doi: 10.1016/j.canlet.2016.05.005
|
13 |
奕伟 范. Study on the Mechanism of Cytokines Influencing Breast Cancer Bone Metastasis in Bone Microenvironment. Advances in Clinical Medicine 2022; 12(06): 5748 doi: 10.12677/ACM.2022.126831
|
14 |
Buyun Kim, Byoungduck Park. Baohuoside I Suppresses Invasion of Cervical and Breast Cancer Cells through the Downregulation of CXCR4 Chemokine Receptor Expression. Biochemistry 2014; 53(48): 7562 doi: 10.1021/bi5011927
|
15 |
Guangping Lu, Jun Li, Jiahui Chu, Shidai Jin, Ziyi Fu, Dengshun Miao, Yongmei Yin. 1,25(OH)2D3 deficiency increases TM40D tumor growth in bone and accelerates tumor-induced bone destruction in a breast cancer bone metastasis model. Biomedicine & Pharmacotherapy 2017; 95: 1033 doi: 10.1016/j.biopha.2017.09.018
|